Ambit Biosciences and Astellas Pharma Inc. Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia at the 54th Annual Meeting of the American Society of Hematology : 4503, Astellas) and Ambit Biosciences Corporation announced today that the results from a completed Phase ... (more)
http://www.biospace.com/news_story.aspx?StoryID=281910&full=1
http://www.biospace.com/news_story.aspx?StoryID=281910&full=1
No comments:
Post a Comment